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Introduction. Clinical observation of larger prostate glands in men with diabetes mellitus type 2 led some investigators to
hypothesize that an association between these two conditions exists. In fact, both diseases are very common in men as they age and
seem to be sharing similar epidemiologic features. Several studies examining the above hypothesis were yielded. Aim. The purpose
ofthispaperistosummarizetheexistingliteraturefocusingonthecoexistenceofBPHanddiabetesmellitustype2andtoelucidate
whether or not an association among these conditions exists. Methods. We identiﬁed studies published from 1990 onwards by
searching the MEDLINE database of the National Library of Medicine. Initial search terms were benign prostatic hyperplasia,
epidemiology,a n drisk factor, combined with diet hyperinsulinemia, and diabetes mellitus type 2. Results. Diabetes mellitus type
2 and hyperinsulinemia are quite common conditions and often coexist with BPH. There are several studies (observational,
epidemiological, and experimental) examining the association between them in literature. Conclusion. Evidence suggests that an
association between BPH and diabetes through a common pathogenic mechanism is possible. The speciﬁc pathway interfering in
the development of both conditions is still poorly investigated; thus, the exact relationship of BPH to diabetes remains unclear.
Copyright © 2009 K. Stamatiou et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Benign prostatic hyperplasia (BPH) is the most common
benign tumor in men, and its incidence is age related. It is
a signiﬁcant public health problem, globally, aﬀecting 50%
of men aged 60 years or older. BPH represents a pattern of
unregulated but nonmalignant growth characterized by an
increase in prostate epithelial and stromal cells, especially
the latter. The etiology of BPH is still largely unresolved,
but multiple partially overlapping and complementary sys-
tems (nerve, endocrine, immune, and vascular) as well
a sl o c a lf a c t o r sa r el i k e l yt ob ei n v o l v e d[ 1, 2]. Although
the speciﬁc pathway remains poorly investigated, it seems
that the pathogenetic mechanism is endocrine controlled
[2].
Controversy surrounding BPH pathogenesis along with
the fact that both BPH and diabetes mellitus type 2 (DM-
2) are both high prevalent diseases is posing doubts on the
association between these two common diseases. On the
other hand, even though BPH and DM-2 are apparently
disparate clinical entities, both diseases seem to be sharing
similar epidemiologic features, which are possibly connected
to a common pathogenic pathway related to aging and diet
[3, 4].
2. Methods
We identiﬁed studies published from 1990 onwards by
searching the MEDLINE database of the National Library
of Medicine. Initial search terms were benign prostatic
hyperplasia,epidemiology,andriskfactor,combinedwithdiet,
hyperinsulinemia, and diabetes mellitus type 2. References
in the selected publications were checked for relevant
publications not included in the Medline/Pubmed search.
3. Results
Bourke and Griﬃn were the ﬁrst to suggest an association
between diabetes mellitus and BPH etiology, based on the2 Advances in Urology
higher prevalence of diabetes mellitus among men subjected
to prostatectomy than in the general male population
[5]. Almost 30 years later, a study by Hammarsten et al.
regenerated the scientiﬁc interest on the association between
these two conditions. They showed that patients with lower
urinary tract symptoms (LUTSs) and DM-2 had larger
prostate volumes than patients with LUTSs without diabetes
mellitus [6]. In addition, Safarinejad and Sarma found a
positive association between clinical markers of BPH and
d i a b e t e sm e l l i t u s[ 7, 8].
SimilarlytoBPH,DMaﬀectsbladderfunctionproducing
both obstructive and irritative symptoms: the classic triad of
obstructive symptoms (diﬃculty initiating voiding, fullness
after voiding, and increased post void residual urine volume)
characterizing diabetic cystopathy is also common in BPH.
Similarly, frequency and urgency are associated with both
DM-induced detrusor instability and BPH. The distinction
between LUTS secondary to DM and LUTS secondary to
BPH is diﬃcult to disentangle, and often LUTS secondary
to DM overlaps LUTS secondary to BPH and vice versa.
Moreover, diabetes considerably contributes to the devel-
opment and the deterioration of LUTS while on the other
hand BPH is not always accompanied by symptoms. It is the
bothersome of the irritative symptoms that make patients
seekmedicalaid.Toourknowledge,theseverysymptomsare
more common among diabetic patients, with 39%–61% of
them having some degree of frequency and urgency [9, 10].
As diabetes aﬀects the voiding function, patients with BPH
and concomitant DM-2 have more bothersome symptoms
and show signiﬁcantly lower maximum ﬂow rate (Qmax)
than nondiabetic BPH patients [11, 12]. For the above
reasons, patients with DM-2 are more prone to be diagnosed
with BPH and subsequently subjected to prostatectomy than
general male population. This fact limits the scientiﬁc value
of the epidemiologic association between BPH and DM2
through LUTS.
Interestingly, other researchers recognized that from
patients with hypertrophy of prostate those with the higher
levels of serum glucose (>110mg/dL) had a considerably
higher mean prostate volume in comparison with patients
with low levels of serum glucose [13, 14]. Furthermore,
Hammarsten and H¨ ogstedt comparing anthropologic char-
acteristics with laboratory and clinical data in patients with
lower urinary tract symptoms with or without manifesta-
tions of the metabolic syndrome demonstrated a further
increase in prostate growth rate with the increase levels
of serum insulin [15]. This observation was conﬁrmed by
Ozden et al. who found considerably higher annual rates of
increase in the volume of the transient area diabetics against
thepatientswithlowlevelsofserumglucose[13].Nandeesha
et al. correlated insulin proﬁle parameters with prostate
size and found fasting serum insulin and insulin resistance
levels signiﬁcantly higher in nondiabetic BPH cases when
comparedtocontrols[16].Recently,Barnardetal.connected
the reduction of growth of stem epithelial prostate cells with
the reduction of insulin [17].
Among other possible mechanisms proposed to associate
the development of BPH with DM-2 are the increase of
the peripheral sympathetic nerve tone and the activity of
autonomous nervous system in general due to hyperin-
sulinemia [18] and hypoxia, due to the decreased blood
supply of the prostate deriving from diabetes mellitus-
induced vascular damage [19]. Taking in consideration the
above information, it could be assumed that abnormalities
of glucose homeostasis could play a role in the cause
of BPH by inﬂuencing the proliferation rate of prostate
cells. The speciﬁc hypothetic mechanisms are diﬃcult to
be identiﬁed. Current knowledge supports the idea of a
growth-stimulating factor mediating the development and
maintenance of the hypertrophic prostate. In fact, insulin
is a growth-stimulating hormone that stimulates growth
and cell reproduction. The presence of growth factors for
prostatic tissue and their role in cellular interactions is
known from older studies [18]. In order to evaluate the role
of activating factors of BPH growth, Wang et al. investigated
the expression of ﬁbroblasts growth factor (ﬁbroblast growth
factor2, FGF2) in the prostates of a capable number of rats
with experimental-induced diabetes mellitus. They found
that the expression of FGF2 was higher in epithelial cells
compared to that of the stromal cells of the prostates of
the control group; however, the expression of FGF2 was
uniformly distributed in the prostates of diabetic group.
Interestingly, the peer presence of FGF2 in the stromal and
the epithelial layers was consistent with the disproportion
in the relation of number of cells of epithelial and stromal
layers that is observed in BPH. They also noticed that
while the diabetic rats had smaller prostates and lower
levels of serum testosterone compared to those of the
control group, treatment with insulin increased both the
size of prostate and the levels of testosterone [19]. In fact,
insulin is a growth hormone that promotes the development
and the reproduction of cells. The presence of insulin-like
growth factor (IGF) has been known for decades to exist in
prostatic tissue. It has been proved also that the prostatic
epithelial cells as well as the stromal cells respond to the
mitogenic action of IGF through IGF-I receptors. Moreover,
it has been proved that the cells of prostatic stromal layer
c o m p o s ea n ds e c r e t eI G F - I Ia sw e l la sc o n j u n c t i v ep r o t e i n s
(IGF-binding proteins/IGFBP) which undergo proteolysis
by Prostate Speciﬁc Antigen (PSA). Deviations in various
elements of IGF system have been observed in the cells
of prostatic stroma in BPH as well [20, 21]. Given the
dependence of the epithelial as well as the stromal cells from
the dihydrotestosterone [22] and the increased activity of
IGF-II in the cells of periurethral area [21]—where BPH
develops—it could supposed that BPH is promoted by IGF
in a male hormone dependent process. Even though such
a process has not been completely described, experimental
models proved that prostate atrophy induced by androgen
deprivation as well as with the eﬀect of antiandrogens
and of 5-a-reductase inhibitors is achieved through local
growth factors [23, 24]. Particularly for the insulin-like
growth factor, experiments proved that its activity is likely
to be regulated by androgens. In the absence of them,
the number of IGFBP is dramatically diminished while
inhibition of testosterone transformation to DHT decreases
both IGF-1 receptors as well as the level of IGF-I mRNA
[25].Advances in Urology 3
4. Conclusion
The exact relationship of BPH to diabetes remains unclear.
The speciﬁc pathway interfering in the development of both
conditionsisstillpoorlyinvestigated.However,evidencesug-
gests that an association between BPH and diabetes through
a common pathogenic mechanism through male hormone
activity alteration mediated by IGF is possible. The above
potentially constitutes the key for the comprehension of the
insulin eﬀect and the abnormalities of glucose homeostasis
in the development of BPH.
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